Q-omics provides the consensus-scored MIR302CHG profile across patient tissues and cancer cell-line models. MIR302CHG expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR302CHG is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, MIR302CHG RNA expression shows 16,638 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, BRCA, and UVM as cancer lineages where MIR302CHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR302CHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR302CHG survival associations across molecular data types. MIR302CHG RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR302CHG RNA expression–survival associations across cancer types. High MIR302CHG expression shows unfavorable associations in KICH, LGG and THCA, but favorable associations in BLCA, SKCM and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR302CHG RNA expression.
This table summarizes MIR302CHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR302CHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR302CHG shows lower tumor expression in BRCA, UCEC, COAD and READ and higher tumor expression in HNSC and CHOL. The BRCA box plot shows higher MIR302CHG RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with MIR302CHG in patient tissues and cancer cell lines. In patient samples, MIR302CHG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
